CSPG4 and cancer: Collectively, daily addition of decitabine for 6 days converts more than half of treated SKOV-3 cells to CSPG4-positive cells, which may render those cancer cells potentially sensitive to CSPG4-directed therapies, such as CSPG4-specific CAR-T cells.